LEXINGTON, Mass., Nov. 14, 2018 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results.
"We remain focused on advancing the clinical development of our Pulmazole program," said Robert W. Clarke, Ph.D., chief executive officer of Pulmatrix. "We are pleased with the progress made in preparing for the upcoming Pulmazole clinical trial and plan to initiate the Phase 2 clinical trial of Pulmazole in patients with asthma and ABPA next month."
Financials
As of September 30, 2018, Pulmatrix had $3.8 million in cash and cash equivalents, compared to $3.6 million as of December 31, 2017.
Research and development expenses for the third quarter of 2018 were $3.1 million, compared to $2.6 million for the same period last year. The increase was primarily due to increases in clinical development costs and external service costs on the Pulmazole program. General and administrative expenses for the third quarter of 2018 were $1.8 million, compared to $2.0 million for the same period last year.
Net loss for the third quarter of 2018 was $4.8 million compared to a net loss of $4.5 million in the same period last year. The increase in net loss was primarily attributable to the noted increases in expenses relating to the Pulmazole program.
About Pulmatrix
Pulmatrix is a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ technology. The Company's proprietary product pipeline is focused on advancing treatments for serious lung diseases, including Pulmazole, an inhaled anti-fungal for patients with allergic bronchopulmonary aspergillosis ("ABPA"), and PUR1800, a narrow spectrum kinase inhibitor for patients with obstructive lung diseases including asthma and chronic obstructive pulmonary disease ("COPD"). Pulmatrix's product candidates are based on iSPERSE™, its proprietary engineered dry powder delivery platform, which seeks to improve therapeutic delivery to the lungs by maximizing local concentrations and reducing systemic side effects to improve patient outcomes.
FORWARD-LOOKING STATEMENTS
Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company cautions that such statements involve risks and uncertainties that may materially affect the Company's results of operations. Such forward-looking statements are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including but not limited to the ability to establish that potential products are efficacious or safe in preclinical or clinical trials; the ability to establish or maintain collaborations on the development of therapeutic candidates; the ability to obtain appropriate or necessary governmental approvals to market potential products; the ability to obtain future funding for developmental products and working capital and to obtain such funding on commercially reasonable terms; the Company's ability to manufacture product candidates on a commercial scale or in collaborations with third parties; changes in the size and nature of competitors; the ability to retain key executives and scientists; and the ability to secure and enforce legal rights related to the Company's products, including patent protection. A discussion of these and other factors, including risks and uncertainties with respect to the Company, is set forth in the Company's filings with the Securities and Exchange Commission, including its annual report on Form 10-K filed by the Company with the Securities and Exchange Commission on March 13, 2018, as may be supplemented or amended by the Company's Quarterly Reports on Form 10-Q. The Company disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Financial Tables to Follow
CONDENSED CONSOLIDATED BALANCE SHEETS | |||
At September 30, | At December 31, | ||
(unaudited) | |||
Assets | |||
Current assets: | |||
Cash and cash equivalents | $ 3,806 | $ 3,550 | |
Prepaid expenses and other current assets | 914 | 696 | |
Total current assets | 4,720 | 4,246 | |
Property and equipment, net | 447 | 614 | |
Long-term restricted cash | 204 | 204 | |
Goodwill | 10,914 | 10,914 | |
Total assets | $ 16,285 | $ 15,978 | |
Liabilities and stockholders' equity | |||
Current liabilities: | |||
Loan payable, net of debt discount and issuance costs | $ — | $ 3,221 | |
Accounts payable | 1,367 | 457 | |
Accrued expenses | 2,284 | 2,162 | |
Derivative liability | — | 1 | |
Total current liabilities | 3,651 | 5,841 | |
Stockholders' equity: | |||
Common stock, $0.0001 par value — 200,000,000 shares authorized; 46,927,221 and 21,047,498 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively | 5 | 2 | |
Additional paid-in capital | 202,856 | 184,137 | |
Accumulated deficit | (190,227) | (174,002 ) | |
Total stockholders' equity | 12,634 | 10,137 | |
Total liabilities, redeemable convertible preferred stock and stockholders' equity | $ 16,285 | $ 15,978 | |
CONDENSED CONSOLIDATED RESULTS OF OPERATIONS | ||
For the Three Months Ended | ||
2018 | 2017 | |
Revenues | $ — | $ 335 |
Operating expenses | ||
Research and development | 3,056 | 2,618 |
General and administrative | 1,769 | 2,021 |
Total operating expenses | 4.825 | 4,639 |
Loss from operations | (4,825) | (4,304) |
Interest expense | — | (153) |
Other income, net | 9 | 5 |
Net loss | $ (4,816) | $ (4,452) |
Net loss per share attributable to common stockholders, basic and diluted | $ (0.10) | $ (0.22) |
Weighted average shares used to compute basic and diluted net loss per share attributable to common stockholders | 46,927,221 | 20,200,893 |
Investor Contact | |
Robert Clarke, CEO | William Duke, CFO |
(781) 357-2333 | (781) 357-2333 |
SOURCE Pulmatrix, Inc.
